The 2016 elections created a lot of excitement among marijuana and CBD supporters, as voters approved marijuana legalization in eight states, including four states (California, Maine, Massachusetts, and Nevada) that will allow recreational marijuana use.
This has policy-makers thinking more approvals could be coming that further expand the legal marijuana market. As such, investors are increasingly looking for stocks that could benefit from growing marijuana use, including drug companies that are seeking to profit from developing marijuana-derived medicines.
This is why when I saw this NightFood Holdings (NGTF) press release I was intrigued.
Before I tell you why the press release intrigued me, let me tell you why NGTF had already been on my radar. They are the first (and currently only) nutrition company to formulate and manufacture sleep-friendly snacks to solve the $50 Billion dollar nighttime craving problem.
Their first product is the NightFood nutrition bar which is selling on on Amazon. The product is highly rated and has been gaining traction since becoming available toward the end of June. The company is also planning a few new snacks including the late night snacking staple ice cream.
So with an already high potential business in place, NGTF announced an initial production run of Half-Baked™ cannabis infused cookies expected to be completed shortly, and product should be on shelf during the month of May 2018.
This would increase NightFood’s “sleep friendliness” and would certainly be a boon for investors.
However, if something were to change the federal laws on CBD the company is still in position to succeed with their already exciting product line.
A few public companies that can benefit from this news include: NightFood Holdings, Inc. (NGTF), GW Pharmaceuticals plc (GWPH), AbbVie, Inc. (ABBV), Cara Therapeutics, Inc. (CARA), General Cannabis Corp. (CANN), and Zynerba Pharmaceuticals, Inc. (ZYNE).
NightFood Holdings, Inc. (NGTF)
Market Cap: $16.99M, current share price: $.4195
NightFood Holdings, Inc. (NGTF), a brand development company pioneering the projected billion-dollar nighttime nutrition category and developing unique products in the marijuana/cannabis/CBD related snack space, recently announced that the Company has entered into its first licensing agreement as part of their plan to build a national brand of popular snacks under the powerful Half-Baked™ brand trademark.
An initial production run of Half-Baked™ cannabis infused cookies is expected to be completed shortly, and product should be on shelf during the month of May 2018.
GW Pharmaceuticals plc (GWPH)
Market Cap: $3.81 B, current share price: $135.17
An advisory panel to the U.S. Food and Drug Administration recently unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.
The drug, Epidiolex, is derived from cannabidiol (CBD), one of the hundreds of molecules found in the marijuana plant, and an FDA decision is expected by June 27.
The syrup contains less than 0.1 percent of tetrahydrocannabinol (THC), the substance that makes people high.
The FDA panel found that the drug’s benefits outweighed the risks to treat patients aged 2 years and older with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.
AbbVie, Inc. (ABBV)
Market Cap: $161.9B, current share price: $102.07
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Their Marinol drug is FDA-approved for the treatment of nausea in patients undergoing chemotherapy and is also prescribed to AIDS patients suffering from loss of appetite. The drug is made of a synthetic form of THC and is delivered as an oral capsule.
ABBV recently submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-23 (IL-23) inhibitor, being evaluated for the treatment of patients with moderate to severe plaque psoriasis.
Cara Therapeutics, Inc. (CARA)
Market Cap: $423.46M, current share price: $12.92
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company, focusing on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. Cara is developing lead molecules that selectively modulate peripheral CB receptors without targeting CNS cannabinoid receptors. Peripheral CB receptor modulators will be initially developed as a novel therapeutic approach for neuropathic and inflammatory pain, a condition currently without consistently effective therapies. Cara’s most advanced CB compound, CR701, is currently in preclinical development.
CARA just released a transcript of their Q1 earnings call: https://finance.yahoo.com/news/edited-transcript-cara-earnings-conference-122442595.html
General Cannabis Corp. (CANN)
Market Cap: $154.13M, current share price: $4.35
CANN, the comprehensive national resource to the regulated cannabis industry, today announced that it completed the closing of a private placement transaction with various private parties, including existing and new investors in General Cannabis.
The Company issued $5.54 million of senior secured promissory notes and an aggregate of 4,432,000 warrants to purchase common stock at the closing. The notes bear interest at 8.5% per annum and are secured by all of the Company’s assets. The warrants have an exercise price of $2.35 per share. If the shares underlying the warrants are not registered for resale on a registration statement within six months, the Company will issue an additional warrant to each investor at the same exercise price for one-half of the shares covered by the initial warrant.
Zynerba Pharmaceuticals, Inc. (ZYNE)
Market Cap: $141.17M, current share price: $10.41
ZYNE, a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare and near-rare neurological and psychiatric disorders with high unmet medical needs, is reporting new longer term open label clinical data today in the Emerging Science session of the 2018 Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, CA.
In a poster presentation entitled, “Transdermal Cannabidiol (CBD) Gel for the Treatment of Focal Epilepsy in Adults” (poster P4.468), Dr. John Messenheimer presents additional data from ongoing STAR 2 (Synthetic Transdermal CAnnabidiol for the TReatment of Epilepsy) 24-month open label extension study evaluating ZYN002 cannabidiol (CBD) transdermal gel in adult patients with focal seizures. The presentation includes data through twelve months of open label exposure to ZYN002.
Verify all claims and do your own due diligence.WealthandKnowledgeReport.com profiles are not a solicitation or recommendation to buy, sell or hold securities. .WealthandKnowledgeReport.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. .WealthandKnowledgeReport.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only .WealthandKnowledgeReport.com has been paid Ten Thousand Dollars for an investor awareness campaign on NGTF. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Neither .WealthandKnowledgeReport.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in.WealthandKnowledgeReport.com statements and opinions and such statements and opinions cannot be considered independent. .WealthandKnowledgeReport.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. WealthandKnowledgeReport.com services are often paid for using free-trading shares. .WealthandKnowledgeReport.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration. All Rights Reserved. Disclaimer E-mail:info@WealthandKnowledgeReport.com